Seroatlas · Human Serome Atlas

CEACAM20

Cell adhesion molecule CEACAM20

Also known as: CEA20_HUMAN, UNQ9366

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q6UY09
Gene: CEACAM20
Ensembl: ENSG00000273777
Chromosome: 19
Canonical length: 596 aa
Protein class: Predicted membrane proteins

OverviewNCBI Gene

Predicted to enable protein tyrosine kinase binding activity. Predicted to be involved in regulation of immune system process and signal transduction. Predicted to be located in apical plasma membrane and microvillus membrane. Predicted to be active in cell surface and plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

596 residues, UniProt reviewed canonical sequence.

>Q6UY09|CEACAM20
     1  MGPADSWGHH WMGILLSASL CTVWSPPAAA QLTLNANPLD ATQSEDVVLP VFGTPRTPQI
    61  HGRSRELAKP SIAVSPGTAI EQKDMVTFYC TTKDVNITIH WVSNNLSIVF HERMQLSKDG
   121  KILTILIVQR EDSGTYQCEA RDALLSQRSD PIFLDVKYGP DPVEIKLESG VASGEVVEVM
   181  EGSSMTFLAE TKSHPPCAYT WFLLDSILSH TTRTFTIHAV SREHEGLYRC LVSNSATHLS
   241  SLGTLKVRVL ETLTMPQVVP SSLNLVENAR SVDLTCQTVN QSVNVQWFLS GQPLLPSEHL
   301  QLSADNRTLI IHGLQRNDTG PYACEVWNWG SRARSEPLEL TINYGPDQVH ITRESASEMI
   361  STIEAELNSS LTLQCWAESK PGAEYRWTLE HSTGEHLGEQ LIIRALTWEH DGIYNCTASN
   421  SLTGLARSTS VLVKVVGPQS SSLSSGAIAG IVIGILAVIA VASELGYFLC IRNARRPSRK
   481  TTEDPSHETS QPIPKEEHPT EPSSESLSPE YRNISQLQGR IRVELMQPPD LPEETYETKL
   541  PSASRRGNSF SPWKPPPKPL MPPLRLVSTV PKNMESIYEE LVNPEPNTYI QINPSV

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against CEACAM20 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.45
Highest tissue expression: 36 nTPM

Expression across tissuesHPA

Tissue

small intestine: 36 nTPM
duodenum: 35 nTPM
prostate: 7.9 nTPM
gallbladder: 0.7 nTPM
testis: 0.5 nTPM
liver: 0.3 nTPM

Single-cell type

enterocytes: 110 nCPM
neuroendocrine cells: 32 nCPM
early spermatids: 8.6 nCPM
prostatic glandular cells: 5.2 nCPM
undifferentiated spermatogonia: 5 nCPM
retinal bipolar cells: 4.7 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

cerebellum: 0.1 nTPM
cerebral cortex: 0.1 nTPM
amygdala: 0 nTPM
basal ganglia: 0 nTPM
choroid plexus: 0 nTPM
hippocampal formation: 0 nTPM

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

protein tyrosine kinase binding

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads CEACAM20 as an antibody target. Whether an autoantibody or antibody against CEACAM20 could matter depends on whether native CEACAM20 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

CEACAM20 is annotated at the cell surface, where native CEACAM20 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label CEACAM20 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...